QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: Signal Management for Biological Medicinal Products

Test your understanding of the concepts covered by Signal Management for Biological Medicinal Products.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which statement best describes the regulatory meaning of a safety signal?

A confirmed causal relationship that requires immediate product withdrawal Information suggesting a new or changed potentially causal association that warrants investigation Any adverse event that is serious and unexpected A statistically significant disproportionality result that establishes incidence

Question 2 of 10 What is the most appropriate interpretation of a high disproportionality measure for a drug–event pair?

The event has a high incidence among exposed patients The medicine caused the event in the reported cases The event is reported more often than expected relative to other drug–event pairs in that database The event is more common with the medicine than in the general population

Question 3 of 10 Which statement best explains why a case-series definition is needed for delayed anaphylaxis after a biological medicine?

It ensures that every report with an anaphylaxis-related term is automatically included It permits consistent inclusion and exclusion and helps distinguish delayed immune reactions from infusion reactions, disease symptoms or excipient allergy It removes the need to review time to onset It converts the case series into an incidence study

Question 4 of 10 Which finding would provide the strongest support for a clinically meaningful antidrug-antibody concern?

A single positive antibody result obtained with an assay of unknown drug tolerance Antibody positivity accompanied by persistent or neutralising activity and compatible changes in pharmacokinetics, efficacy or hypersensitivity Antibody positivity measured only after treatment without any baseline information A change in antibody assay methodology with no clinical outcomes

Question 5 of 10 Which proposed action best matches an issue confirmed as a defective injector lot causing incomplete doses?

A class-wide label change concerning immunogenicity only Targeted quality containment and field action, with evaluation of clinical consequences and effectiveness No action until a large epidemiological study proves causality Aggregation of the issue with all injection-site reactions

Question 6 of 10 What is the best interpretation of repeated reports with an unknown batch number?

The reports demonstrate that batch identity is irrelevant The reports should be excluded from all signal analyses The missing information is a data-quality limitation that should be monitored and addressed The reports prove that all batches are equally affected

Question 7 of 10 Which governance arrangement is most consistent with an inspection-ready biological signal-management system?

Unwritten responsibilities with decisions made by whichever function first reviews a case Defined methods, review frequency, ownership, escalation routes, competence, QPPV access and traceable decision records A single statistical threshold applied to every product regardless of exposure or risk Separate pharmacovigilance and quality systems with no formal information exchange

Question 8 of 10 A report describes loss of effect after a patient switched products but does not list the prior product or the switch date. What is the principal limitation?

The report cannot be used for any purpose The missing sequence prevents reliable product-specific attribution and makes dosing gaps, expectation effects and prior exposure difficult to assess The event must be classified as a class effect The report proves that switching caused the outcome

Question 9 of 10 Which statement best reflects the relationship between signal closure and ongoing surveillance?

Closure means the event must be removed from routine monitoring Closure requires a documented conclusion and action disposition, while residual uncertainty and routine surveillance may remain Closure is appropriate whenever no disproportionality threshold is exceeded Closure can occur before regulatory and quality actions are tracked

Question 10 of 10 A company internally agrees that a validated hypothesis should be analysed. How should this decision be described in EU signal-management terminology?

It is automatically regulatory confirmation It is a signal closure decision It is an internal governance decision and should not be misrepresented as regulatory confirmation It is equivalent to a positive benefit–risk conclusion

QPPV.com

Knowledge Assessment: Signal Management for Biological Medicinal Products

Cookie Settings